Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The company’s wholly-owned subsidiary, Zhejiang Health Road Technology Group Co., Ltd., is the entity involved in the sale [1] - The decision to sell the stake is driven by the need to reduce costs and improve efficiency amid disappointing financial performance [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became apparent, leading to a significant drop in revenue and net profit starting August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1] Group 3: Future Plans - Proceeds from the sale will be used to develop the company’s enterprise services and digital marketing services [1]

Core Viewpoint - Health Road (02587.HK) announced the sale of a 51% stake in its subsidiary, Fujian Jianchen Pharmaceutical Co., Ltd., to Ms. Xiao Jing for a total consideration of RMB 1.6779 million, effective December 24, 2025. Following the sale, the subsidiary will no longer be part of the company's consolidated financial statements [1]. Group 1 - The sale is driven by the temporary revenue increase from stockpiling Oseltamivir during the flu outbreak at the end of 2023, which highlighted the limitations of the subsidiary as a single-product pharmaceutical wholesaler [1]. - Since August 2024, the subsidiary's performance has declined significantly due to unmet expectations from drug procurement agreements with other pharmaceutical companies, leading to a substantial drop in revenue and net profit [1]. - The company aims to use the proceeds from the sale to develop its enterprise services and digital marketing services, focusing on cost reduction and efficiency improvement [1].

Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The sale is being conducted by Zhejiang Health Road Technology Group Co., Ltd., a wholly-owned subsidiary of the company [1] - The proceeds from the sale will be used to develop the company's enterprise services and digital marketing services [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became evident, leading to a significant drop in revenue and net profit starting from August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 於本公告日期，出 售 公 司 為 本 公 司 的 間 接 非 全 資 附 屬 公 司，由 賣 方 及 買方分別持有51%及49%股 權。買 方 為 出 售 公 司 的 主 要 股 東 及 董 事；因 此，根 據 上 市 規 則 第14A.07(1)條，彼 為 本 公 司 附 屬 公 司 層 面 的 關 連 人 士。因 此，根 據 上 市 規 則 第14A章，出 售 事 項 構 成 本 公 司 的 關 連 交 易。 根據上市規則第14A.101條，由 於(1)買 方 為 附 屬 公 司 層 面 的 關 連 人 士； (2)董 事 會 已 批 准 出 售 事 項；及(3)獨立非執行董事已確認出售事項的條 款屬公平合理及出售事項按一般商業條款或更佳條款訂立且符合本 公 司 及 其 股 東 的 整 體 利 益，故 出 售 事 項 須 遵 守 上 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 临近岁末，港股多只次新股集中迎来限售股解禁，考验市场流动性。 12月23日，多只次新股因限售股解禁股价走低，药捷安康-B、周六福单日跌幅高达18.08%、17.05%， 越疆、佑驾创新、三花智控等6只次新股单日跌幅超过5%。 Wind数据统计显示，12月23日至12月31日，合计有13只次新股面临限售股解禁压力，以12月22日收盘 价计，解禁总市值高达674亿港元。业内人士认为，次新股解禁可能会阶段性冲击市场流动性，但个股 的长期表现取决于公司质地。 4只次新股超半数股份解禁 12月23日，越疆开盘后大幅下挫，早盘股价一度重挫超15%。此后跌幅虽有所收窄，但全天仍未能扭转 跌势，最终收跌8.08%，报收29港元/股。 越疆在港股上市刚满一年。按照此前公告安排，越疆大股东、股权激励平台、领航资深独立投资者等投 资者遵守禁售承诺至2025年12月22日，这意味着越疆在今年6月份基石投资者持股解禁后，再迎新一批 限售股解禁。此次解禁的限售股数量约3.14亿股，占流通股的比例为79.7%。 同日，还有药捷安康-B、三花智控面临限售股解禁。Win ...

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Health Road (02587.HK) by 891,000 shares on December 22, while there were three days of net increases totaling 588,600 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings on nine occasions, resulting in a total net reduction of 503,400 shares [1] - Currently, southbound funds hold 185 million shares of Health Road, which accounts for 21.08% of the company's total issued ordinary shares [1] Group 2 - Health Road Holdings Limited primarily engages in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates its business through three segments: enterprise services and digital marketing services, health care services, and other health services and products sold through various online and offline channels [1] - The enterprise services and digital marketing services segment includes content services, information technology services, and digital marketing services, while the health care services segment focuses on medical support services and value-based medical services [1]

Summary of the Food and Beverage Industry Conference Call Industry Overview - The food and beverage industry is expected to end its deep adjustment cycle by 2026, with consumer goods having largely completed inventory destocking [1][4] - The liquor sector, particularly baijiu, is projected to reach a new equilibrium by Q2 2026, with CPI stabilizing to alleviate price deflation pressures [1][4] - Companies with innovation or supply chain optimization capabilities are expected to stand out in the recovery phase [1][4] Key Insights and Arguments - The liquor sector is currently in a bottoming process, with mid-term investment value being significant [1][5] - Consumer goods are benefiting from an efficiency revolution and the transition between old and new growth drivers, with emerging channels and cost advantages continuing [1][5] - In 2025, the food and beverage sector showed mixed performance, with yellow wine, soft drinks, dairy products, and meat products leading in growth, while baijiu faced significant downward pressure from high-end price declines [1][6] Market Dynamics - The CPI and PPI differential has been volatile, with weak price increase expectations; however, a future stabilization of CPI could relieve downward price pressures [1][7] - The liquor price average has returned to a high level, indicating limited future downward space, necessitating companies to maintain a balance between volume and price [1][8] Sector-Specific Trends Liquor Industry - The baijiu sector is expected to reach a new balance by Q2 2026, with a characteristic of low-to-high price movement [1][5] - Companies are advised to focus on maintaining volume-price balance during the destocking phase [1][8] Consumer Goods - The industry is currently in a "channel is king" phase, necessitating the exploration of structural opportunities to meet changing consumer demands for health, personalization, convenience, and cost-effectiveness [1][9] - After completing inventory destocking, traditional sectors may rebound, with new emerging segments expected to thrive [1][9] Dairy Industry - The dairy sector is in a stabilization phase, with raw milk supply expected to contract in 2026, leading to a potential improvement cycle [1][11] - Key companies to watch include Yili, Mengniu, and Miaokelando, which are expected to show growth potential [1][11] Beer and Yellow Wine - The beer industry is stable but experiencing changes due to the rise of new channels, suggesting a focus on leading companies like Qingdao Beer and Yanjing Beer [1][12] - The yellow wine sector is seeing a concentration of market share among leading companies, with structural upgrades expected to continue [1][12] Soft Drinks and Snacks - The soft drink market is facing intensified competition, with notable segments like glucose tea and sports drinks showing promise [1][13] - The snack sector is benefiting from new channel transformations, with companies like Weilong and Chacha expected to perform well [1][13] Restaurant Supply Chain and Food Chains - The restaurant supply chain is recovering from regulatory impacts, with companies like Anji Food and Gaoli Co. being highlighted for their growth potential [1][14] - Food chain companies are accelerating their expansion through optimization and innovation, presenting investment opportunities [1][14] Health Products - The health product market shows potential for significant growth, with key products like coenzyme Q10 and probiotics gaining traction [1][15] Conclusion - Each sub-sector within the food and beverage industry presents unique opportunities and challenges, necessitating tailored investment strategies to capture alpha opportunities and achieve stable returns [1][16]

Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index closed at 4429.87 points, with an increase of 0.88% on December 19, and a trading volume of 14.95 billion HKD, resulting in a turnover rate of 2.21% [1] - Among the constituent stocks, 43 companies experienced an increase, with Health Road leading the gain at 4.82%, while 14 companies saw a decline, with Sanofi Biologics leading the drop at 2.31% [1] Group 2 - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 841 million HKD, while retail funds saw a net inflow of 536 million HKD and speculative funds had a net inflow of 305 million HKD [2]

Core Viewpoint - Southbound funds increased their holdings in Health Road (02587.HK) by 27,600 shares on December 17, while experiencing net reductions in holdings over the past trading days [1] Group 1: Southbound Fund Activity - Over the last 5 trading days, southbound funds reduced their holdings on 3 days, with a total net reduction of 14,900 shares [1] - In the last 20 trading days, there were 10 days of reductions, totaling a net decrease of 4,331,900 shares [1] - Currently, southbound funds hold 184 million shares of Health Road, representing 20.98% of the company's issued ordinary shares [1] Group 2: Company Overview - Health Road Holdings Limited is primarily engaged in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates through three segments: enterprise services and digital marketing services, health care services, and other health services and products [1] - The enterprise services and digital marketing segment includes content services, information technology services, and digital marketing services [1] - The health care services segment provides medical support services and value-based medical services [1] - The other segment offers various health services and products through online and offline channels, including patient visitation services and nutritional supplements [1] - The company primarily conducts its business in the domestic market [1]

智通财经APP讯，健康之路(02587)发布公告，于2025年12月17日，该公司斥资41.04万港元回购9.4万股 股份，每股回购价格为4.27-4.41港元。 ...